Ongoing research is exploring the potential of Brentuximab Vedotin in combination with other therapies, such as immunotherapies and chemotherapy, to enhance its efficacy further. Additionally, studies are investigating its use in other CD30-positive malignancies and its role in earlier lines of treatment. As our understanding of cancer biology and drug mechanisms evolves, Brentuximab Vedotin's role in the oncology landscape may expand, offering hope to more patients.
